Inhibiting immune suppression in cancer
Tumours are known to evade immune responses, thereby limiting the efficacy of immunotherapy and vaccination efforts. Although cancer cells express aberrant glycosylation patterns, their immunosuppressive role has been largely overlooked. The EU-funded MGLycan project will focus on the macrophage galactose-type lectin (MGL), the key receptor on immune cells that recognises aberrant sugars on cancer cells. MGL is overexpressed in macrophages and dendritic cells during immune suppression. The main objective of the project is to design inhibitors that block the MGL interaction with cancer cells, blocking downstream signalling that culminates in immune suppression.
Fields of science
Call for proposalSee other projects for this call
Funding SchemeMSCA-IF-EF-ST - Standard EF
20009 San Sebastian
See on map